At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 24, 2026 at 20:00 ET
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open-market share sales totaling approximately $504,000 over a two-day period, concurrent with the exercise of stock options. The sales represent a coordinated liquidity event following derivative exercises, but the dollar amount is small relative to the company's $3.8B market cap.
- CEO Catherine Owen Adams sold $249,932 worth of shares, CFO Mark Schneyer sold $158,332, and other C-suite executives sold an additional $95,766 in open-market transactions.
- All sales were preceded by or concurrent with the exercise of stock options (M-coded transactions), indicating pre-planned option monetization rather than discretionary selling of held shares.
- Total open-market sale value across all insiders: ~$504,000 over two days.
- Total value represents only 0.013% of Acadia's $3.8B market cap, well below the 0.1% threshold for materiality.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access